Quay Pharma, a contract development and manufacturing organization (CDMO), has been acquired by SGS, the Swiss-based (TIC) Testing, Inspection and Certification company.
 
The acquisition provides Quay with the investment to further grow its range of services and capabilities to support pharmaceutical clinical development, from pre-clinical to formulation, dosage form design and optimization, as well as clinical trial manufacture and supply.
 
In particular, it will enhance the development of Quay’s pioneering work in live biotherapeutics, and the company’s expansion in the U.S., where it recently opened a dedicated sales office and development and manufacturing facility in the Greater Boston area.
 
“This is an exciting and significant milestone for Quay,” commented the company’s CEO Maireadh Pedersen. “As part of SGS, we will be able to accelerate our growth strategy and further develop our range of services, with the introduction of additional capabilities such as biopharmaceutical analysis and specialist microbiological capabilities.
 
“At the same time, we will retain our existing management and dedicated specialist teams to ensure we continue to offer our clients the highest levels of service, expertise and technical focus, coupled with a flexible approach, on which our success has been built.”
 
Quay will become part of SGS Health Science and be the company’s global Centre of Excellence for Formulation, Research and Development.
 
Frankie Ng, CEO of SGS said, “This acquisition supports our strategic evolution by further aligning our global network ever more closely to TIC megatrends. Quay Pharma adds a significant level of competence to the Group and allows us to offer more comprehensive and complex, high value-added services to our customers.”
 
SGS is a leading testing, inspection and certification company, recognized as the global benchmark for quality and integrity. The company employs 93,000 people across a network of 2,600 offices and labs.